vs

Side-by-side financial comparison of DULUTH HOLDINGS INC. (DLTH) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

Tarsus Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($151.7M vs $114.9M, roughly 1.3× DULUTH HOLDINGS INC.). Tarsus Pharmaceuticals, Inc. runs the higher net margin — -5.5% vs -8.8%, a 3.3% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs -9.6%). Tarsus Pharmaceuticals, Inc. produced more free cash flow last quarter ($13.0M vs $-8.9M). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs -31.6%).

Duluth Holdings Inc., which primarily sells goods through its Duluth Trading Company brand, is an American workwear and accessories company.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

DLTH vs TARS — Head-to-Head

Bigger by revenue
TARS
TARS
1.3× larger
TARS
$151.7M
$114.9M
DLTH
Growing faster (revenue YoY)
TARS
TARS
+138.0% gap
TARS
128.4%
-9.6%
DLTH
Higher net margin
TARS
TARS
3.3% more per $
TARS
-5.5%
-8.8%
DLTH
More free cash flow
TARS
TARS
$21.9M more FCF
TARS
$13.0M
$-8.9M
DLTH
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
-31.6%
DLTH

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
DLTH
DLTH
TARS
TARS
Revenue
$114.9M
$151.7M
Net Profit
$-10.1M
$-8.4M
Gross Margin
53.8%
Operating Margin
-7.7%
-5.3%
Net Margin
-8.8%
-5.5%
Revenue YoY
-9.6%
128.4%
Net Profit YoY
64.6%
63.8%
EPS (diluted)
$-0.29
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DLTH
DLTH
TARS
TARS
Q4 25
$114.9M
$151.7M
Q3 25
$131.7M
$118.7M
Q2 25
$102.7M
$102.7M
Q1 25
$241.3M
$78.3M
Q4 24
$127.1M
$66.4M
Q3 24
$141.6M
$48.1M
Q2 24
$116.7M
$40.8M
Q1 24
$245.6M
$27.6M
Net Profit
DLTH
DLTH
TARS
TARS
Q4 25
$-10.1M
$-8.4M
Q3 25
$1.3M
$-12.6M
Q2 25
$-15.3M
$-20.3M
Q1 25
$-5.6M
$-25.1M
Q4 24
$-28.2M
$-23.1M
Q3 24
$-2.0M
$-23.4M
Q2 24
$-7.9M
$-33.3M
Q1 24
$6.4M
$-35.7M
Gross Margin
DLTH
DLTH
TARS
TARS
Q4 25
53.8%
Q3 25
54.7%
Q2 25
52.0%
Q1 25
44.1%
Q4 24
52.3%
Q3 24
52.3%
Q2 24
52.8%
Q1 24
48.2%
Operating Margin
DLTH
DLTH
TARS
TARS
Q4 25
-7.7%
-5.3%
Q3 25
1.8%
-12.2%
Q2 25
-12.0%
-21.6%
Q1 25
-1.8%
-33.5%
Q4 24
-17.4%
-36.8%
Q3 24
-1.1%
-52.3%
Q2 24
-7.7%
-81.6%
Q1 24
3.6%
-136.5%
Net Margin
DLTH
DLTH
TARS
TARS
Q4 25
-8.8%
-5.5%
Q3 25
1.0%
-10.6%
Q2 25
-14.9%
-19.8%
Q1 25
-2.3%
-32.1%
Q4 24
-22.2%
-34.8%
Q3 24
-1.4%
-48.7%
Q2 24
-6.7%
-81.6%
Q1 24
2.6%
-129.4%
EPS (diluted)
DLTH
DLTH
TARS
TARS
Q4 25
$-0.29
$-0.17
Q3 25
$0.04
$-0.30
Q2 25
$-0.45
$-0.48
Q1 25
$-0.17
$-0.64
Q4 24
$-0.84
$-0.57
Q3 24
$-0.06
$-0.61
Q2 24
$-0.24
$-0.88
Q1 24
$0.20
$-1.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DLTH
DLTH
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$8.2M
$417.3M
Total DebtLower is stronger
$72.4M
Stockholders' EquityBook value
$160.6M
$343.4M
Total Assets
$468.0M
$562.2M
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DLTH
DLTH
TARS
TARS
Q4 25
$8.2M
$417.3M
Q3 25
$5.7M
$401.8M
Q2 25
$8.6M
$381.1M
Q1 25
$3.3M
$407.9M
Q4 24
$9.3M
$291.4M
Q3 24
$9.8M
$317.0M
Q2 24
$6.8M
$323.6M
Q1 24
$32.2M
$298.5M
Total Debt
DLTH
DLTH
TARS
TARS
Q4 25
$72.4M
Q3 25
$72.3M
Q2 25
$72.1M
Q1 25
$72.0M
Q4 24
$71.8M
Q3 24
$71.7M
Q2 24
$71.6M
Q1 24
$29.9M
Stockholders' Equity
DLTH
DLTH
TARS
TARS
Q4 25
$160.6M
$343.4M
Q3 25
$170.0M
$335.1M
Q2 25
$167.9M
$332.6M
Q1 25
$182.7M
$342.5M
Q4 24
$188.1M
$224.5M
Q3 24
$215.7M
$237.5M
Q2 24
$218.4M
$252.2M
Q1 24
$222.8M
$275.2M
Total Assets
DLTH
DLTH
TARS
TARS
Q4 25
$468.0M
$562.2M
Q3 25
$433.8M
$534.6M
Q2 25
$463.7M
$495.0M
Q1 25
$452.4M
$500.8M
Q4 24
$533.1M
$377.0M
Q3 24
$488.6M
$376.3M
Q2 24
$471.4M
$376.8M
Q1 24
$491.2M
$349.3M
Debt / Equity
DLTH
DLTH
TARS
TARS
Q4 25
0.21×
Q3 25
0.22×
Q2 25
0.22×
Q1 25
0.21×
Q4 24
0.32×
Q3 24
0.30×
Q2 24
0.28×
Q1 24
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DLTH
DLTH
TARS
TARS
Operating Cash FlowLast quarter
$-6.7M
$19.3M
Free Cash FlowOCF − Capex
$-8.9M
$13.0M
FCF MarginFCF / Revenue
-7.8%
8.6%
Capex IntensityCapex / Revenue
2.0%
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$1.7M
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DLTH
DLTH
TARS
TARS
Q4 25
$-6.7M
$19.3M
Q3 25
$32.0M
$18.3M
Q2 25
$-56.5M
$-29.4M
Q1 25
$41.2M
$-20.7M
Q4 24
$-41.1M
$-22.2M
Q3 24
$16.6M
$-8.7M
Q2 24
$-33.7M
$-14.4M
Q1 24
$69.7M
$-37.8M
Free Cash Flow
DLTH
DLTH
TARS
TARS
Q4 25
$-8.9M
$13.0M
Q3 25
$29.8M
$16.3M
Q2 25
$-57.8M
$-30.4M
Q1 25
$38.7M
$-21.2M
Q4 24
$-43.7M
$-22.3M
Q3 24
$15.0M
$-8.9M
Q2 24
$-35.2M
$-15.4M
Q1 24
$60.6M
$-38.0M
FCF Margin
DLTH
DLTH
TARS
TARS
Q4 25
-7.8%
8.6%
Q3 25
22.6%
13.8%
Q2 25
-56.3%
-29.6%
Q1 25
16.0%
-27.1%
Q4 24
-34.4%
-33.5%
Q3 24
10.6%
-18.6%
Q2 24
-30.2%
-37.8%
Q1 24
24.7%
-137.5%
Capex Intensity
DLTH
DLTH
TARS
TARS
Q4 25
2.0%
4.2%
Q3 25
1.7%
1.6%
Q2 25
1.3%
1.0%
Q1 25
1.0%
0.8%
Q4 24
2.1%
0.1%
Q3 24
1.2%
0.6%
Q2 24
1.3%
2.5%
Q1 24
3.7%
0.6%
Cash Conversion
DLTH
DLTH
TARS
TARS
Q4 25
Q3 25
25.40×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
10.86×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DLTH
DLTH

Sales Channel Directly To Consumer$67.4M59%
Sales Channel Through Intermediary$47.4M41%

TARS
TARS

Segment breakdown not available.

Related Comparisons